Table 1.
Baseline characteristics of patients by group.
| Ivermectin (n = 12) | Placebo (n = 12) | |
|---|---|---|
| Age, median (IQR)[range] (years) | 26 (19–36) [18–54] | 26 (21–44) [18–54] |
| Sex, No. (%) | ||
| Female | 5 (42%) | 7 (58%) |
| Male | 7 (58%) | 5 (42%) |
| Body mass index, median (IQR) [range] kg/m2 | 23·5 (19·6–27·8) [18·6–29· 9] | 22·9 (21·0–24·8) [19·3–29·9] |
| Symptoms | ||
| Any, No. (%) | 12 (100%) | 12 (100%) |
| Fever, No. (%) | 7 (58%) | 9 (75%) |
| Cough, No. (%) | 4 (33%) | 2 (17%) |
| Headache, No. (%) | 7 (58%) | 10 (83%) |
| Myalgia/general malaise, No. (%) | 8 (67%) | 6 (50%) |
| Earliest start of any symptoma, median, (IQR) [range] | 24 (24–48) [18–120] | 48 (36–48) [24–72] |
| Earliest start of fevera*, No, median. (IQR) [range] | 24 (12–24) [12–24], n = 7 | 24 (24–48) [4–48], n = 9 |
| Earliest start of cougha, No, median. (IQR) [range] | 24 (16–36) [8–48], n = 4 | 10 (8–12) [8–12], n = 2 |
| Vital signs | ||
| Systolic Blood pressure, median. (IQR), mmHg | 114 (113–117) | 129 (116–134)b |
| Diastolic blood pressure, median. (IQR), mmHg | 76 (72–80) | 79 (77–85) |
| Heart rate, median (IQR), bpm | 83 (77–99) | 90 (81–100) |
| Respiratory rate, median (IQR), bpm | 14 (12–17) | 14 (12–15) |
| Temperature, median (IQR), °C | 36·8 (36·4–37·0) | 36·9 (36·5–37·0) |
| Oxygen saturation, median (IQR),% | 97 (96–98) | 98 (97–100) |
| Viral load | ||
| Gene E, No. (IQR), copies/ml | 1·7·107 (5·9·106- 3·9·108) | 2·7·107 (8·3·105- 4·2·108) |
| Gene N, No. (IQR), copies/ml | 3·7·108 (1·8·107- 9·3·109) | 3·3·108 (5·8·107- 6·7·109) |
| Inflammatory markers | ||
| CRP, median (IQR), mg/dL [normal value] | 0·3 (0·2–0·8) [<0·5] | 0·3 (0·2–0·6) [<0·5] |
| Ferritin, median (IQR), mg/dL [normal value] | 165·0 (95·8 - 241·3) [30–400] | 156·1 (103·1–223·0) [30–400] |
| IL-6, median (IQR), pg/mL [normal value] | 6·5 (5·1 - 9·6) [<7] | 4·5 (3·0–6·5) [<7] |
| D-Dimer, median (IQR), ng/mL [normal value] | 295 (270–420) [150–500] | 280 (270–315) [150–500] |
| Full blood count | ||
| Red blood cells, median (IQR), 1012/L | 5·05 (4·62–5·55) | 5·07 (4·67– 5·45) |
| Hemoglobin, median (IQR), g/dL | 15·3 (13·8–16·0) | 15·2 (13·7–15·8) |
| Platelets, median (IQR), 109/L | 194 (167–216) | 205 (179–247) |
| White blood cells, median (IQR), 109/L | 4·7 (4·3–6·3) | 4·4 (3·7–5·9) |
| Neutrophils, median (IQR),% | 52·4 (45·6–65·1) | 53·4 (43·9–62·2) |
| Lymphocytes, median (IQR),% | 29·5 (18·5- 7·9) | 28·7 (20·8–39·9) |
a
Hours before dosing
b
The slightly higher median systolic blood pressure in the placebo group at baseline was not seen in subsequent study visits and was judged as non-clinically significant, see table S3 for the evolution of all vital signs throughout the study, *Reported or measured fever. IQR: interquartile range